studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), nivolumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33] CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30] CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.78 [0.60; 1.02] 0.96[0.80; 1.15]CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018343%1,327moderatenot evaluable progression or deaths (PFS)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44] CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45] CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.73 [0.56; 0.95] 1.00[0.76; 1.33]CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018377%1,327moderatenot evaluable objective responses (ORR)detailed resultsCheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06] 0.70[0.46; 1.06]CheckMate 026 (PDL1>5%), 201610%423NAnot evaluable STRAE (any grade)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.75 [1.00; 3.09] 1.25[0.67; 2.31]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018266%885moderatenot evaluable STRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33] CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.05 [1.12; 3.76] 1.27[0.52; 3.13]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018281%885moderatenot evaluable TRAE (any grade)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34] CheckMate 227 (NC vs C ; PDL1<1%), 2018 3.42 [1.76; 6.65] 0.83[0.05; 13.17]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018298%885moderatenot evaluable TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31] CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.35 [1.53; 3.60] 0.70[0.07; 7.49]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018298%885moderatenot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 227 (NC vs C ; PDL1<1%), 2018 4.33 [0.48; 39.16] 4.33[0.48; 39.16]CheckMate 227 (NC vs C ; PDL1<1%), 201810%355NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20] CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.89 [0.48; 1.63] 0.78[0.52; 1.16]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 201820%885moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40] CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.80 [0.38; 1.70] 1.02[0.62; 1.68]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 201820%885moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.34 [0.75; 2.38] 0.17[0.00; 11.79]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018294%885moderatenot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.07; 17.15] 0.38[0.05; 3.18]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 201829%885moderatenot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09] 1.97[0.07; 59.09]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.26 [0.01; 5.89] 0.44[0.04; 5.01]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 201820%885moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48] 0.71[0.13; 3.87]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018241%885moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.15; 7.64] 0.72[0.23; 2.31]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 201820%885moderatenot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71] CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.18 [0.65; 7.39] 0.67[0.06; 6.88]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018286%885moderatenot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94] 1.19[0.36; 3.94]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07] 3.51[0.72; 17.07]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92] 0.05[0.00; 0.92]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09] 1.97[0.07; 59.09]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67] CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.85 [0.22; 3.21] 0.52[0.13; 2.03]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018223%885moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.19 [0.63; 2.24] 0.17[0.00; 11.82]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018289%885moderatenot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83] 0.98[0.02; 49.83]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.02; 53.93] 0.68[0.05; 8.94]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 201820%885moderatenot evaluable Pyrexia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72] 0.49[0.02; 14.72]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94] CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.13 [0.07; 64.04] 2.03[0.28; 14.47]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 201820%885moderatenot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09] 1.97[0.07; 59.09]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19] 12.07[0.67; 217.19]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsCheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09] 5.00[0.58; 43.09]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72] 0.49[0.02; 14.72]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31] 0.04[0.01; 0.31]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 0.10 [0.01; 1.78] CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48] 0.50[0.04; 6.57]CheckMate 026 (PDL1>1%), 2016, CheckMate 227 (NC vs C ; PDL1<1%), 2018261%885moderatenot evaluable Increase AST AE (grade 3-4)detailed resultsCheckMate 026 (PDL1>1%), 2016 7.05 [0.86; 57.74] 7.05[0.86; 57.74]CheckMate 026 (PDL1>1%), 201610%530NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:22 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 855,360,719,721,720,842,642,674,1085,863